ABCL - AbCellera Biologics Inc.

2.07
-0.100   -4.831%

Share volume: 4,781,746
Last Updated: 04-10-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.01%

PREVIOUS CLOSE
CHG
CHG%
$2.17
-0.10
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 9%
Dept financing 7%
Liquidity 58%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.98%
1 Month
-7.17%
3 Months
-31.00%
6 Months
-20.08%
1 Year
-52.74%
2 Year
-71.57%
Key data
Stock price
$2.07
P/E Ratio 
0.00
DAY RANGE
$1.97 - $2.12
EPS 
-$0.55
52 WEEK RANGE
$1.89 - $4.34
52 WEEK CHANGE
-$52.30
MARKET CAP 
865.423 M
YIELD 
N/A
SHARES OUTSTANDING 
294.666 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
1.27
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$4,607,571
AVERAGE 30 VOLUME 
$3,813,423
Company detail
CEO: Carl Lars G. Hansen
Region: US
Website: abcellera.com
Employees: 500
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AbCellera Biologics Inc. has 156 discovery programs that are either completed, in progress, or under contract with 36 partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Recent news
loading